The incidence and risk factors for thyroid disorders among adult survivors of allogeneic hematopoietic stem cell transplantation (alloHCT) is not well known. This study evaluated incidence and risk factors of thyroid dysfunction in 259 adult alloHCT recipients who had survived for 2 years or more after transplant. Median follow-up was 4.6 years (range; 2.3 to 15.4 years). The 5-year cumulative incidence of thyroid dysfunction was 30.5% (79 of 259 patients). Majority of thyroid abnormalities were observed beyond 2 years after alloHCT. Subclinical hypothyroidism was the most common thyroid abnormalities accounting for 89% of cases (71 patients). Among these, treatment with thyroid replacement was eventually started in 44% (31 patients). Based on the multivariate analysis, thyroid abnormality was more likely in patients who received high-dose (≥12 Gy) total body irradiation (TBI)-based conditioning regimen compare to low-dose TBI-based (≤500 cGy) and non-TBI-conditioning regimen (p = 0.032). This risk was further augmented directly proportional with the time from alloHCT. These data identify high-dose TBI-conditioning regimen as a risk factor for thyroid dysfunction in adult recipients of alloHCT.
Introduction
Allogeneic hematopoietic cell transplantation (alloHCT) is potentially a curative treatment option for variety of hematologic diseases, genetic conditions, and immunedeficiencies. Advances in the field of alloHCT over the past decade due to safer conditioning regimens, better posttransplant supportive care, and alternative graft sources has markedly increased the number of HCTs performed leading to increase in the longevity of survivors. The number of alloHCT survivors is estimated to increase to 242,000 survivors by the year 2020 and 502,000 survivors by the year 2030 [1] . This success has also brought the recognition of the long-term health impact of HCT [2, 3] .
Thyroid dysfunction is among the most common longterm endocrine complications post alloHCT [4] . Based on international Blood and Marrow transplant (BMT) guidelines, thyroid function assessment is recommended yearly after HCT or in presence of relevant symptoms [5] . Total body irradiation (TBI), younger age at transplantation, and presence of graft-versus-host disease (GVHD) are the most recognized risk factors for thyroid dysfunction after alloHCT [6] [7] [8] [9] [10] . Most studies of thyroid dysfunction after alloHCT have been conducted in pediatric recipients of alloHCT. There are currently very limited data on incidence and risk factors of thyroid dysfunction after alloHCT in adults [11, 12] . These studies have been limited by small sample sizes, short follow-up duration, and conflicting results, thus the clear incidence and risk factors of post-HCT thyroid abnormalities in adults remains unclear. Herein we report our experience with thyroid dysfunction in long-term survivors of alloHCT and describe the predictors of nonmalignant thyroid abnormalities.
Study design

Patients
This retrospective investigational study was carried out utilizing the Mayo Clinic's transplant center database. After institutional review board approval, we evaluated 887 patients older than 18 years of age at the time of transplantation, who underwent alloHCT between December 2006 and December 2014. Long-term survivors in this study are defined as individuals who are alive and disease free at least 2 years after receiving alloHCT since most deaths after HCT occur within the first 2 years as a result of relapse, acute or chronic GVHD and infectious complications [13] .
At our institution, all patients routinely have thyroid function testing at a scheduled interval of 100 days after alloHCT and yearly afterwards. More frequent evaluation may be performed as medically indicated. For the purpose of this study, patients were considered evaluable if serial monitoring of thyroid function test were performed. Individuals with abnormal thyroid function test prior to alloHCT were excluded. Therefore, total of 259 patients were included in the final analysis.
Definitions of thyroid dysfunction
Thyroid dysfunction was defined as first occurrence of thyroid function abnormality based on serum thyroid function testing. Subclinical hypothyroidism is defined as serum TSH level above the upper limit of the reference range, with a serum T3/T4 level within the reference range. Overt primary hypothyroidism is defined as elevated TSH with low serumT3 and/or T4. Subclinical hyperthyroidism is defined as suppressed TSH with normal T3/T4 levels while overt hyperthyroidism is diagnosed in presence of elevated serum T3 and/or T4 and suppressed TSH.
Statistical analysis
Patients are classified based on whether they have developed thyroid dysfunction or not. Fisher's exact test and t test is used to assess univariate association of the thyroid dysfunction status with a given categorical covariate, or a continuous covariate. Univariate association of time from the transplant to the onset of thyroid dysfunction and each of the covariates was analyzed by Cox regression analysis.
Multivariate logistic regression and Cox regression with stepwise selection procedure were also performed to search for important risk factors for the thyroid dysfunction. Initial variables for the multivariate model included gender, age at transplant, primary disease, donor type (related vs. unrelated), stem cell source (peripheral blood stem cell vs. bone marrow vs. others), intensity of conditioning chemotherapy (myeloablative (MA) vs. reduced intensity (RIC)), TBI-containing preparative regimen (yes vs. no), TBI dose (Low dose vs. high dose) and chronic GVHD (yes vs. no). As all patients included in this study has survived more than 2 years post-transplant, chronic GVHD was analyzed as a categorical variable. Cumulative incidences between the low-dose TBI (TBI dose 500cGy or less) vs. the high-dose TBI group (1200cGyor more) were compared and tested with the Gray's test where deaths from any other causes were treated as a competing risk. All analyses were performed using SAS 9.4 software.
Results
A total of 386 out of 887 alloHCT recipients who survived at least 2 years after HCT were identified for analysis. Two hundred abd fifty-nine patients among those had evaluable clinical and laboratory parameters available (Fig. 1) . The characteristics of the final cohort of patients included in this study for analysis are shown in Table 1 . In the entire cohort, the median follow-up time was 4.6 years (range; 2.3 to 15.4 years).
Out of 259 patients, 79 (30.5% of the total cohort) developed thyroid dysfunction after alloHCT. Specifically, 71 (89%) cases of subclinical hypothyroidism, 6 (8%) cases of overt primary hypothyroidism, and 2 (3%) cases of hyperthyroidism (one subclinical and one overt) were found. The majority of thyroid abnormalities were identified beyond 2 years post alloHCT with 29% of the thyroid dysfunction seen in first year, 13% in second year and 58% beyond the 2 years. The median interval between alloHCT Table 2 . Median age at transplantation was 50 (range, 18 to 67 years). The primary disease was nonmalignant (severe aplastic anemia) in three patients, and hematologic malignancies in 76 cases. Majority of the patients with thyroid dysfunction received TBI-containing conditioning regimen (54 patients, 68%). Among the 54 patients, TBI dose was myeloablative in 46 (85%) and reduced intensity in 8 (15%) patients. Subclinical hypothyroidism accounted for majority of thyroid abnormality seen in 89% of cases (71 patients) with thyroid dysfunction. Among these, treatment with thyroid replacement was eventually started in 44% (31 patients).
Patients characteristics based on thyroid function status Table 1 summarizes the baseline patient-related, diseaserelated, and transplantation-related characteristics of the subjects included in this study. The factors evaluated for association with thyroid function status included age at transplant, gender, underlying disease, stem cell source, donor source, conditioning regimen (myeloablative vs. reduced intensity), use of TBI, and chronic GVHD. There were no significant differences among the two cohorts (cohort with thyroid dysfunction and without thyroid dysfunction) when evaluated by gender, disease subtype, stem cell source, and the presence or absence of chronic GVHD. There was significantly greater number of patients with matched related donor, myeloablative preparative regimen, TBI-based conditioning regimen, and high-dose TBI (dose ≥12 Gy) in the cohort with thyroid abnormality post alloHCT.
Univariate analysis of pre-transplantation factors related to time to thyroid dysfunction
The same set of factors evaluated in Table 1 were also tested for their association with time from the transplant to the onset of thyroid dysfunction with Cox regression model ( Table 2 ). Univariate analysis demonstrated that there were statistically significant differences in the TBI doses groups (no TBI/low TBI vs. high-dose TBI) with regard to risk for development of thyroid dysfunction overtime from alloHCT (Figs. 2, 3) . Administration of high-dose TBI conditioning was significantly associated with increased risk of thyroid dysfunction (Fig. 2) . The cumulative incidences among the three TBI groups were further compared and tested with the Gray's test where deaths from any other cause were treated as a competing risk. The Gray test was significant (P = 0.032) indicating non-violation of proportional hazard assumption. There were no significant differences in development of thyroid dysfunction among all patients when evaluated by gender, disease subtype, stem cell source, and presence of chronic GVHD. 
Discussion
Among the endocrinopathies, thyroid dysfunction is the most common late effect in alloHCT survivors and its lifelong surveillance is currently recommended post-transplant. The incidence and risk factors for thyroid abnormality after alloHCT has been studied extensively in pediatrics. As opposed to pediatrics, there is a paucity of information regarding incidence and risk factors for thyroid disorders among adult alloHCT recipients. Our study is the largest study to date evaluating incidence and risk factors for thyroid dysfunction in adult long-term survivors of alloHCT.
Based on a few studies in literature, the reported incidence of thyroid dysfunction after alloHCT ranges from 10 to 47% in adults [14] [15] [16] . Relatively short duration of follow-up and small number of patients contribute to wide variability in incidence of thyroid dysfunction seen in these studies. In our study, approximately one third of the patients (30.5%) developed thyroid dysfunction with median follow-up of approximately~5 years. Majority of thyroid abnormalities were observed beyond 2 years after alloHCT, highlighting the persistent risk of thyroid disease long post alloHCT and the need for long-term screening.
Statistical analysis in the present study identified the dose of TBI as the only risk factor for thyroid dysfunction in adult alloHCT recipients. There was a significant increase in rate of thyroid disease after high-dose TBI-based conditioning (≥1200 cGY) compared with lowdose TBI-based (≤500 cGy) and non-TBI-conditioning regimen (P = 0.032). This risk was further augmented directly proportional with the time from alloHCT. High doses of TBI is a well-established risk factor for thyroid dysfunction in a pediatric recipient of alloHCT. However, there is very limited information on association between dose of radiation and thyroid dysfunction in adults. Our finding is in contrary to the two prior studies that evaluated impact of intensity of TBI-based regimen on thyroid dysfunction in adults. In retrospective study, Al Fier et al. evaluated the effect of three doses of TBI (as component of myeloablative-conditioning regimen) on thyroid function in a cohort of 270 adult recipients of alloHCT [12] . Among the 270 patients only 24 (8.8%) developed thyroid abnormalities post-transplant. The incidence of hypothyroidism was 8.9, 3.8, and 7.2% in patients receiving TBI doses 300 cGy, 500 cGy, and 1200 cGy, respectively. This trend did not reach a statistical significance. In the study by Al Fier et al., a small number of thyroid dysfunction detected due to relatively short duration of follow-up may have led to insufficient power to detect significance.
Al Hazzouri et al., also evaluated the impact of TBI dose on incidence of thyroid abnormality in a retrospective cohort of 180 adults who received TBI-based conditioning regimen prior to alloHCT [17] . Similar risk for hypothyroidism was observed among recipients of MA TBIbased and RIC TBI-based conditioning regimens. Threeyear cumulative incidence of hypothyroidism was 3% and 5% among MA and RIC alloHCT recipients, retrospectively. In contrast to our study, median age of RIC cohort was significantly older compare to MA cohort (54-year-old vs. 37-year-old; P < 0.01) in the study by Al Hazzouri. In general population, the prevalence of thyroid disorders increases with age. Therefore, advantages of lower dose of TBI (RIC) may have been offset by older age of RIC cohort.
Besides dose of radiation, in the present study there was no statistically significant association in adult long-term alloHCT survivors between thyroid dysfunction and patient or transplant characteristics including age, gender, underlying disease, hematopoietic cell source, donor type, and presence or absence of (limited or extensive) chronic GVHD. Impact of chronic GVHD on development of thyroid disease post alloHCT is not well studies. In a retrospective study of 81 adult alloHCT recipients, Savani et al. reported a significant association between prolonged chronic GVHD requiring long-term immunosuppressant (more than 3 years) and thyroid dysfunction [14] . There was no significant difference in rate of thyroid abnormality among patients with extensive or limited chronic GVHD, as seen in our study. These results highlight the importance of duration of immunosuppression therapy for chronic GVHD rather than presence or absence or severity of chronic GVHD as a risk factor for thyroid dysfunction after alloHCT.
In our cohort, we did not identify any cases of thyroid cancer among the alloHCT survivors. Based on prior reports, the latency period between thyroid irradiation and the clinical presentation of a thyroid malignancy may be a decade or more, thus median follow-up duration of 5 years may have not been long enough for detection of thyroid carcinoma. In one of the largest pediatric studies evaluating thyroid function after alloHCT, 0.02% of patients (18 of 791 patients) developed thyroid tumors (13 papillary carcinoma and 5 benign tumors) at a median of 9.9 years [7] . In addition, pediatric patients are more prone to development of radiation-related cancer than adults partly due to mutagenic effects of ionizing radiation on growing tissue.
Despite having a large sample size (887 patients) and evaluation of multiple-risk factors, our study has many limitations which are inherent to all retrospective reviews. Comprehensive testing with a full autoimmune panel of thyroid dysfunction was not available for evaluation, thus limiting our ability to ascertain the possible autoimmune etiology of this problem, which is now a well-recognized entity causing thyroid failure in patients post alloHCT [18] . We also did not have detailed data on the long-term impact of thyroid dysfunction on the quality of life of the HCT survivors, an area which has become extremely important in the current era of patient centered care.
In conclusion, the current study underlines importance of high-dose TBI-based conditioning regimen as risk factors for the development of thyroid dysfunction in adult alloHCT survivors and emphasizes the need for prospectively evaluating this groups' thyroid status on a long-term basis. We also recommend the use of appropriate measures of defined outcomes of success in management of thyroid dysfunction, particularly regarding patients' quality of life.
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